fda semaglutide warning november 2025 Diabetes advocacy group discourages use of compounded GLP-1 drugs FDA Sends Warning Letters to

If you have reduced kidney function, protein targets should be determined by your nephrologist, and standard keto protein recommendations may need downward adjustment

Discussion While GLP-1 RAs are powerful anti-obesity medications (AOMs), they do raise some serious concerns most notably, up to 40% of the profound weight loss induced by these agents can be due to loss of lean mass 3,4,5 and prior studies have shown that a significant portion of this lean mass is muscle 33,34,35

Fortified foods offer another option

Both medications can significantly reduce hunger and food intake

2019, doi:10.1177/1179558119874042